Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Downgrades Clarus Therapeutics Hldgs to Hold

Needham Downgrades Clarus Therapeutics Hldgs to Hold

Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.

byBenzinga Newsdesk

August 23, 2022

1 minute read

Needham analyst Serge Belanger downgrades Clarus Therapeutics Hldgs (NASDAQ:CRXT) from Buy to Hold.

Analyst Ratings

Analyst Scoreboard: 4 Ratings For Electronic Arts

By Benzinga Insights

March 27, 5:00 PM

In the preceding three months, 4 analysts have released ratings for Electronic Arts (NASDAQ:EA), presenting a wide array…

Credit Suisse Initiates Coverage On Charles River with Outperform Rating, Announces Price Target of $285

By Benzinga Newsdesk

August 25, 5:17 AM

Credit Suisse analyst Katie Tryhane initiates coverage on Charles River (NYSE:CRL) with a Outperform rating and announces Price Target of $285.

CRL

Amcon Distributing Q4 EPS $28.59 Up From $11.00 YoY

By Benzinga Newsdesk

November 23, 5:12 PM

Amcon Distributing (AMEX:DIT) reported quarterly earnings of $28.59 per share. This is a 159.91 percent increase over earnings of $11.00 per share from the same period last year.

DIT

UBS Maintains Buy on Bilibili, Lowers Price Target to $30

By Benzinga Newsdesk

September 9, 7:52 AM

UBS analyst Felix Liu maintains Bilibili (NASDAQ:BILI) with a Buy and lowers the price target from $40 to $30.

BILI

Needham Downgrades Clarus Therapeutics Hldgs to Hold

Related Posts

Analyst Scoreboard: 4 Ratings For Electronic Arts

Credit Suisse Initiates Coverage On Charles River with Outperform Rating, Announces Price Target of $285

Amcon Distributing Q4 EPS $28.59 Up From $11.00 YoY

UBS Maintains Buy on Bilibili, Lowers Price Target to $30